Edition:
United States

Intelgenx Technologies Corp (IGX.V)

IGX.V on TSX Venture Exchange

0.99CAD
--
Change (% chg)

-- (--)
Prev Close
$0.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,066
52-wk High
$1.35
52-wk Low
$0.61

Latest Key Developments (Source: Significant Developments)

Intelgenx reports Q1 loss per share C$0.01
Thursday, 11 May 2017 04:01pm EDT 

May 11 (Reuters) - Intelgenx Technologies Corp :Intelgenx reports first quarter 2017 financial results.Q1 loss per share C$0.01.  Full Article

Intelgenx Technologies says Q1 revenue rose 65 pct to $1.4 mln
Thursday, 11 May 2017 04:01pm EDT 

May 11 (Reuters) - Intelgenx Technologies Corp :Intelgenx reports first quarter 2017 financial results.Qtrly revenues reached $1.4 million, an increase of 65% over same period last year.Intelgenx Technologies Corp - qtrly net comprehensive loss was $0.01 on a basic and diluted per share.Intelgenx - as of March 31, 2017, cash, cash equivalents, short-term investments totalled $3.9 million, versus approximately $4.5 million at December 31, 2016.  Full Article

Intelgenx and Redhill Biopharma announce marketing approval of rizaport for migraines
Thursday, 13 Apr 2017 06:00am EDT 

Intelgenx Technologies Corp - : Intelgenx and Redhill Biopharma announce marketing approval of rizaport(r) for migraines in Luxembourg . Co, Redhill expect to re-submit rizaport 505(b)(2) new drug application to FDA in q3 of 2017 .Cos are continuing discussions with additional potential commercialization partners for rizaport in U.S. , Europe, other territories.  Full Article

Intelgenx Technologies Corp files for offering of debentures up to C$10 mln
Wednesday, 5 Apr 2017 12:14pm EDT 

Intelgenx Technologies Corp :Intelgenx Technologies Corp files for offering of 8 pct convertible unsecured subordinated debentures due June 30, 2020 of up to C$10 million - sec filing.  Full Article

Intelgenx and Tetra Bio-Pharma sign agreement for dronabinol xl tablet
Monday, 3 Apr 2017 08:00am EDT 

Intelgenx Technologies Corp :Intelgenx and Tetra Bio-Pharma announce the signing of a definitive agreement for the development and commercialization of a dronabinol xl tablet.  Full Article

Tetra Bio-Pharma, Intelgenx sign agreement for development, commercialization of Dronabinol XL tablet
Monday, 3 Apr 2017 08:00am EDT 

Tetra Bio-pharma Inc : Tetra Bio-pharma and Intelgenx announce the signing of a definitive agreement for the development and commercialization of a Dronabinol XL tablet . Tetra Bio-pharma Inc - definitive agreement follows binding term sheet between two companies that was announced on February 9, 2017 . Tetra Bio-Pharma Inc - pursuant to definitive agreement, Tetra has exclusive rights to sell product in North America .Tetra Bio-Pharma Inc - Tetra will have a right of first negotiation for territories outside of United States and Canada.  Full Article

Intelgenx Technologies says Eli Lilly granted Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent
Tuesday, 28 Mar 2017 08:10am EDT 

Intelgenx Technologies Corp : Intelgenx Technologies- Eli Lilly granted Intelgenx' Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent . Intelgenx Technologies Corp - any exclusivity associated with tadalafil compound patent expiring is not affected by this agreement - SEC filing . Intelgenx Technologies- exclusive license allows co to commercialize tadalafil ed versafilm product in U.S. prior to expiration of '166 dosing patent Source: (http://bit.ly/2nvYskj) Further company coverage: [IGX.V] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Tetra Bio-Pharma, Intelgenx sign ageement to develop and commercialize a dronabinol XL tablet
Thursday, 9 Feb 2017 08:30am EST 

Intelgenx Technologies Corp : Tetra Bio-Pharma and Intelgenx announce the signing of a term sheet for the development and commercialization of a dronabinol XL tablet . Tetra Bio-Pharma - Intelgenx will be responsible for research and development of product, including clinical studies and will develop product as an oral mucoadhesive tablet .Tetra Bio-Pharma - Tetra will make a non-refundable exclusive negotiation payment to Intelgenx, an upfront payment along with set milestone payments.  Full Article

Intelgenx Q3 EPS $0.00
Thursday, 10 Nov 2016 04:00pm EST 

Intelgenx Technologies Corp : Qtrly revenue was $1.8 million, compared to $2.4 million over same period last year . Q3 earnings per share $0.00 .Intelgenx reports profitable third quarter with increased growth in revenues from second quarter.  Full Article

Intelgenx Technologies posts Q3 earnings per share $0.00
Thursday, 10 Nov 2016 04:00pm EST 

Intelgenx Technologies Corp : Intelgenx Reports profitable third quarter with increased growth in revenues from second quarter . Intelgenx Technologies Corp- qtrly revenue was $1.8 million, compared to $2.4 million over same period last year .Q3 earnings per share $0.00.  Full Article

More From Around the Web

BRIEF-Intelgenx reports Q1 loss per share C$0.01

* Q1 loss per share C$0.01 Source text for Eikon: Further company coverage: